GlaxoSmithKline PLC — Director's Dealing 2017

Mar 6, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending 06 March 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company' )

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them
('PCA') — Name | Mr S A
Hussain | |
| --- | --- | --- | --- |
| b) | Position/status | President,
Global Pharmaceuticals | |
| c) | Initial
notification/ amendment | Initial
Notification | |
| 2. | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline
plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary
shares of 25 pence each ('Ordinary Shares') ISIN:
GB0009252882 | |
| b) | Nature
of the transaction | The
sale of 98,581.776 Ordinary Shares on 6 March 2017 at a price of
£16.8006. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £16.8006 | 98,581.776 |
| d) | Aggregated
information | n/a
(single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date of
the transaction | 2017-03-06 | |
| f) | Place
of the transaction | London
Stock Exchange (XLON) | |

| 1. — a) | Details
of PDMR/person closely associated with them ('PCA') — Name | Mrs S G
Hussain | |
| --- | --- | --- | --- |
| b) | Position/status | PCA of
Mr S A Hussain (President, Global Pharmaceuticals) | |
| c) | Initial
notification/ amendment | Initial
Notification | |
| 2. | Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor | | |
| a) | Name | GlaxoSmithKline
plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted | | |
| a) | Description
of the financial instrument | Ordinary
shares of 25 pence each ('Ordinary Shares') ISIN:
GB0009252882 | |
| b) | Nature
of the transaction | The
sale of 131,418 Ordinary Shares on 6 March 2017 at a price of
£16.835. | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | £16.835 | 131,418 |
| d) | Aggregated
information | n/a
(single transaction) | |
| | Aggregated
volume Price | | |
| e) | Date of
the transaction | 2017-03-06 | |
| f) | Place
of the transaction | London
Stock Exchange (XLON) | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: March
06, 2017
By: VICTORIA
WHYTE
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc

page break